NEW YORK (GenomeWeb News) – Response Biomedical today reported that its third-quarter revenues rose 39 percent, while its net loss fell around 14 percent.

The genetic test maker brought in revenues of C$2 million (US$1.9 million) for the three-month period ended Sept. 30, compared to revenues of C$1.5 million in the period last year.

Most of that revenue boost came from the firm’s clinical products business, which increased 62 percent to around C$1.7 million compared with approximately C$1 million a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.